164 related articles for article (PubMed ID: 31473468)
61. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
62. Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.
Laforet M; Jourde-Chiche N; Haddad F; Sallee M; Stoppa AM; Brunet P; Dussol B; Burtey S; Gondouin B
Blood Cancer J; 2016 Mar; 6(3):e409. PubMed ID: 27015286
[No Abstract] [Full Text] [Related]
63. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
64. Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients.
Scudla V; Bacovsky J; Indrak K; Kodouskova V; Vytrasova M; Faber E; Papajik T; Adam Z; Hajek R; Horak P; Martinek A;
Hematol J; 2003; 4(5):351-7. PubMed ID: 14502261
[TBL] [Abstract][Full Text] [Related]
65. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Ailawadhi S; Jagannath S; Lee HC; Narang M; Rifkin RM; Terebelo HR; Durie BGM; Toomey K; Hardin JW; Gasparetto CJ; Wagner L; Omel JL; He M; Yue L; Flick ED; Agarwal A; Abonour R;
Cancer; 2020 Oct; 126(19):4332-4340. PubMed ID: 32706404
[TBL] [Abstract][Full Text] [Related]
66. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.
Jurczyszyn A; Davila J; Kortüm KM; Jayabalan DS; Vij R; Fiala M; Milunovic V; Chim CS; Wiśniewska-Piąty K; Waszczuk-Gajda A; Crusoe E; Hajek R; Robak P; Raźny M; Zawirska D; Bittrich M; Nahi H; Liu J; Castillo JJ; Vesole DH
Leuk Lymphoma; 2019 Feb; 60(2):471-476. PubMed ID: 30033832
[TBL] [Abstract][Full Text] [Related]
67. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.
Engelhardt M; Ihorst G; Landgren O; Pantic M; Reinhardt H; Waldschmidt J; May AM; Schumacher M; Kleber M; Wäsch R
Haematologica; 2015 Oct; 100(10):1340-9. PubMed ID: 26160877
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.
Kang J; Hong JY; Yoon DH; Kim S; Lee KM; Park JS; Park CJ; Min WK; Seo EJ; Jang S; Suh C
Acta Haematol; 2018; 139(3):185-192. PubMed ID: 29635247
[TBL] [Abstract][Full Text] [Related]
69. Epidemiology of multiple myeloma in Taiwan, a population based study.
Tang CH; Liu HY; Hou HA; Qiu H; Huang KC; Siggins S; Rothwell LA; Liu Y
Cancer Epidemiol; 2018 Aug; 55():136-141. PubMed ID: 29957398
[TBL] [Abstract][Full Text] [Related]
70. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.
Lee JH; Lee DS; Lee JJ; Chang YH; Jin JY; Jo DY; Bang SM; Kim HJ; Kim JS; Kim K; Eom HS; Min CK; Yoon SS; Kim SH; Suh C; Cho KS;
Int J Hematol; 2010 Jul; 92(1):52-7. PubMed ID: 20544403
[No Abstract] [Full Text] [Related]
71. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
72. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Kim K; Lee JH; Kim JS; Min CK; Yoon SS; Shimizu K; Chou T; Kosugi H; Suzuki K; Chen W; Hou J; Lu J; Huang XJ; Huang SY; Chng WJ; Tan D; Teoh G; Chim CS; Nawarawong W; Siritanaratkul N; Durie BG
Am J Hematol; 2014 Jul; 89(7):751-6. PubMed ID: 24723430
[TBL] [Abstract][Full Text] [Related]
73. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
74. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.
Thorsteinsdottir S; Dickman PW; Landgren O; Blimark C; Hultcrantz M; Turesson I; Björkholm M; Kristinsson SY
Haematologica; 2018 Sep; 103(9):e412-e415. PubMed ID: 29567776
[No Abstract] [Full Text] [Related]
75. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
76. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
77. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
78. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
[TBL] [Abstract][Full Text] [Related]
79. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
80. Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.
Kumar S; Williamson M; Ogbu U; Surinach A; Arndorfer S; Hong WJ
Cancer Med; 2021 Sep; 10(17):5866-5877. PubMed ID: 34402201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
